The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Click here ...

Compass Pathways (CMPS), on Wednesday, said the U.S. Food and Drug Administration (FDA) has accepted its Investigational New ...

Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...

Compass Pathways (NASDAQ:CMPS) shares rose nearly 9% premarket on Friday after the biotechnology company priced a securities offering to raise up to $353M. The company is offering ~24.01M American ...

The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can ...

COMPASS Pathways PLC Sponsored ADR (CMPS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Compass Pathways plc (NASDAQ:CMPS) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD). Despite meeting the ...

Analyst expectations are far above the prices you'd need to pay now to own a couple of biotechnology stocks. Compass Pathways is developing psilocybin as a treatment for depression. Viking ...